. Severe haemophilia results in increased mortality and poorer quality of life. Factor prophylaxis leads to a more normal life, but is very costly; most of the cost is due to the high cost of replacement factor. Despite its high cost, factor prophylaxis has been adopted throughout the developed world even in different health care systems. We argue that there are at least five possible reasons why societies may value factor prophylaxis despite its cost: (i) it is directed towards an inherited disease, (ii) the treatment is largely directed towards children, (iii) the disease is rare and the overall cost to society is small, (iv) the treatment is preventative, and v) the high cost is largely the result of providing safe products. In an era of rising health care costs, there is a strong research agenda to establish the factors that determine the value of expensive therapies for rare diseases like haemophilia.

Haemophilia prophylaxis: how can we justify the costs? / B. M., Feldman; K., Berger; R., Bohn; M., Carcao; K., Fischer; A., Gringeri; K., Hoots; Mantovani, LORENZO GIOVANNI; A. R., Willan; W., Schramm. - In: HAEMOPHILIA. - ISSN 1351-8216. - STAMPA. - 18:(2012), pp. 680-684. [10.1111/j.1365-2516.2012.02790.x]

Haemophilia prophylaxis: how can we justify the costs?

MANTOVANI, LORENZO GIOVANNI;
2012

Abstract

. Severe haemophilia results in increased mortality and poorer quality of life. Factor prophylaxis leads to a more normal life, but is very costly; most of the cost is due to the high cost of replacement factor. Despite its high cost, factor prophylaxis has been adopted throughout the developed world even in different health care systems. We argue that there are at least five possible reasons why societies may value factor prophylaxis despite its cost: (i) it is directed towards an inherited disease, (ii) the treatment is largely directed towards children, (iii) the disease is rare and the overall cost to society is small, (iv) the treatment is preventative, and v) the high cost is largely the result of providing safe products. In an era of rising health care costs, there is a strong research agenda to establish the factors that determine the value of expensive therapies for rare diseases like haemophilia.
2012
Haemophilia prophylaxis: how can we justify the costs? / B. M., Feldman; K., Berger; R., Bohn; M., Carcao; K., Fischer; A., Gringeri; K., Hoots; Mantovani, LORENZO GIOVANNI; A. R., Willan; W., Schramm. - In: HAEMOPHILIA. - ISSN 1351-8216. - STAMPA. - 18:(2012), pp. 680-684. [10.1111/j.1365-2516.2012.02790.x]
File in questo prodotto:
File Dimensione Formato  
2012_Haemophilia.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 71 kB
Formato Adobe PDF
71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/512806
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact